Fritextsökning
Innehållstyper
-
EUR 2 million for peanut allergies
ALK Abelló has signed an agreement to invest EUR 2 million in the French biotechnology company DBV Technologies.
-
Floppat diabetesvaccin visar positiv effekt
Nya forskningsresultat visar att Diamyd-vaccinets immunologiska effekt håller i sig fyra år efter behandling.
-
Athera signs production partnership
The companys novel cardiovascular product will be manufactured in Germany.
-
Biotage is regrouping
The Swedish company Biotage takes yet another step in streamlining efforts, by outsourcing all instrument production to contract manufacturers.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
Acadia drug awarded
Acadia Pharmaceutical has got an award for a new treatment against Parkinson's disease.
-
Novo och Astra ligger bra till i internationell kraftmätning
Patentutgångar kommer under de närmaste åren att drabba flera stora läkemedelsbolag, men Astrazeneca och Novo Nordisk hör till de som skymtar ljusglimtar enligt en analys.
-
Mingling types - who to aim for and who to avoid:
Read about different mingling types - who are you?
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Medicult acquires embryo scanner
The Danish company Medicult signs an agreement with Novocellus to gain access to embryo selection technology.
-
Vitrolife wants to acquire Medicult
The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.
-
Orion cuts 205 jobs
The Finnish company Orion has completed its statutory negotiations. By this, personnel will be reduced by about 205 in Finland.
-
Your partnering tool - step by step
Profile, agenda and requests. Those are the basic steps to follow to use the partnering tool for Biotech Forum. Follow our guide to successful partnering!
-
How to be a perfect mingler
Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, ...
-
A platform for dialogue
As a step towards connecting the life science industry in Denmark, Biologue was founded three years ago with 10 member companies. Today, the network has 40 memb...
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
-
Early stage research and low turnaround dominates
Nordic science parks are full of advanced research performed by small companies but little research is done in later stages. Only a couple of the best performer...
-
Young, bright and committed to labtech
Ghazal Voghoui recently bought her first apartment and finally settled in Stockholm again. Last year, she finished her law studies and she is relieved to be back after living in Geneva for four years. On November 10 she will take a big career leap...
-
Enjoy Stockholm - the capital of Scandinavia
Welcome to Stockholm! Built on 14 islands, you are never far from the water in the capital of Sweden. Stockholm offers a wide range of museums, theaters, and at...
-
”Alla skriker efter talang”
Att locka till sig begåvningarna är en av life science-branschens stora framtidsutmaningar. Det var en av slutsatserna i det panelsamtal som avslutade konferensen New Horizons in Biologics & Bioprocessing på torsdagen....
-
Ambassador program makes MVA big in Japan
The first ambassadors of the Medicon Valley Ambassador Programme have only worked in each other's countries for six months. But they have already made a signifi...
-
Ideon - Sweden's oldest science park
Old is not synonymous with boring. Swedens oldest science park Ideon still manages to attract young companies with big ideas. The recipe for success? To continu...
-
Konferens om läkemedelsformuleringar samlar branschen i Köpenhamn
Idag pågår den tionde upplagan av New Updates in Drug Formulation & Bioavailability 2022 i Köpenhamn.
-
Martin Bergö: "The Idea is the Thing"
Martin Bergö, 38, goes wherever ideas take him - it's a process that has led to, and resulted from, plenty of unexpected results. Those ideas have been recogniz...